Silvia Bagnoli

Dr. Silvia Bagnoli

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2007 in Neuroscience Letters
Verified
Journal Article
Closed access
SBSilvia Bagnoli
Silvia Bagnoli
ECElena Cellini
Elena Cellini
ATAndrea Tedde
Andrea Tedde
Benedetta NacmiasBenedetta Nacmias
Benedetta Nacmias
SPSilvia Piacentini
Silvia Piacentini
SSSandro Sorbi
Sandro Sorbi

2 April 2013 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
SBSilvia Bagnoli
Silvia Bagnoli
IPIrene Piaceri
Irene Piaceri
ATAndrea Tedde
Andrea Tedde
VBValentina Bessi
Valentina Bessi
LBLaura Bracco
Laura Bracco
Benedetta NacmiasBenedetta Nacmias
Benedetta Nacmias

Verified
Journal Article
Open access
PDF file
GGGiulia Giacomucci
Giulia Giacomucci
SMSalvatore Mazzeo
Salvatore Mazzeo
SBSilvia Bagnoli
Silvia Bagnoli
MCMatteo Casini
Matteo Casini
SPSonia Padiglioni
Sonia Padiglioni
VBValentina Bessi
Valentina Bessi
Background: The aims of this study were to compare the diagnostic accuracy, sensitivity, specificity, and positive and negative predictive values (PPV, NPV) of different cerebrospinal fluid (CSF) amyloid biomarkers and amyloid-Positron Emission Tomography (PET) in patients with a clinical diagnosis of Alzheimer’s disease (AD) and Frontotemporal Dementia (FTD); to compare concordance between biomarkers; and to provide an indication of their use and interpretation. Methods: We included 148 patients (95 AD and 53 FTD), who underwent clinical evaluation, neuropsychological assessment, and at least one amyloid biomarker (CSF analysis or amyloid-PET). Thirty-six patients underwent both analyses. One-hundred-thirteen patients underwent Apolipoprotein E (ApoE) genotyping. Results: Amyloid-PET presented higher diagnostic accuracy, sensitivity, and NPV than CSF Aβ1–42 but not Aβ42/40 ratio. Concordance between CSF biomarkers and amyloid-PET was higher in FTD patients compared to AD cases. None of the AD patients presented both negative Aβ biomarkers. Conclusions: CSF Aβ42/40 ratio significantly increased the diagnostic accuracy of CSF biomarkers. On the basis of our current and previous data, we suggest a flowchart to guide the use of biomarkers according to clinical suspicion: due to the high PPV of both amyloid-PET and CSF analysis including Aβ42/40, in cases of concordance between at least one biomarker and clinical diagnosis, performance of the other analysis could be avoided. A combination of both biomarkers should be performed to better characterize unclear cases. If the two amyloid biomarkers are both negative, an underlying AD pathology can most probably be excluded.

Verified
Journal Article
Open access
PDF file
VBValentina Bessi
Valentina Bessi
JBJuri Balestrini
Juri Balestrini
SBSilvia Bagnoli
Silvia Bagnoli
SMSalvatore Mazzeo
Salvatore Mazzeo
GGGiulia Giacomucci
Giulia Giacomucci
Benedetta NacmiasBenedetta Nacmias
Benedetta Nacmias
Background: Some genes could interact with cardiovascular risk factors in the development of Alzheimer’s disease. We aimed to evaluate the interaction between ApoE ε4 status, Clock T3111C and Per2 C111G polymorphisms with cardiovascular profile in Subjective Cognitive Decline (SCD) and Mild Cognitive Impairment (MCI). Methods: We included 68 patients who underwent clinical evaluation; neuropsychological assessment; ApoE, Clock and Per2 genotyping at baseline; and neuropsychological follow-up every 12–24 months for a mean of 13 years. We considered subjects who developed AD and non-converters. Results: Clock T3111C was detected in 47% of cases, Per2 C111G in 19% of cases. ApoE ε4 carriers presented higher risk of heart disease; Clock C-carriers were more frequently smokers than non C-carriers. During the follow-up, 17 patients progressed to AD. Age at baseline, ApoE ε 4 and dyslipidemia increased the risk of conversion to AD. ApoE ε4 carriers with history of dyslipidemia showed higher risk to convert to AD compared to ApoE ε4− groups and ApoE ε4+ without dyslipidemia patients. Clock C-carriers with history of blood hypertension had a higher risk of conversion to AD. Conclusions: ApoE and Clock T3111C seem to interact with cardiovascular risk factors in SCD and MCI patients influencing the progression to AD.

Verified
Journal Article
Open access
PDF file
SMSalvatore Mazzeo
Salvatore Mazzeo
FEFilippo Emiliani
Filippo Emiliani
SBSilvia Bagnoli
Silvia Bagnoli
SPSonia Padiglioni
Sonia Padiglioni
LRLorenzo Maria Del Re
Lorenzo Maria Del Re
VBValentina Bessi
Valentina Bessi
Patients with idiopathic normal pressure hydrocephalus (iNPH) frequently show pathologic CSF Aβ42 levels, comparable with Alzheimer’s Disease (AD). Nevertheless, the clinical meaning of these findings has not been fully explained. We aimed to assess the role of AD CSF biomarkers (Aβ42, Aβ42/Aβ40, p-tau, t-tau) in iNPH. To this purpose, we enrolled 44 patients diagnosed with iNPH and 101 with AD. All the patients underwent CSF sampling. We compared CSF biomarker levels in iNPH and AD: Aβ42 levels were not different between iNPH and AD, while Aβ42/Aβ40, p-tau, and t-tau were significantly different and showed excellent accuracy in distinguishing iNPH and AD. A multiple logistic regression analysis showed that Aβ42/Aβ40 was the variable that most contributed to differentiating the two groups. Furthermore, iNPH patients with positive Aβ42/Aβ40 had higher p-tau and t-tau than iNPH patients with negative Aβ42/Aβ40. Those iNPH patients who showed cognitive impairment had lower Aβ42/Aβ40 and higher p-tau than patients without cognitive impairment. We concluded that positive CSF Aβ42 with negative Aβ42/Aβ40, p-tau, and t-tau is a typical CSF profile of iNPH. On the contrary, positive Aβ42/Aβ40 in iNPH patients, especially when associated with positive p-tau, may lead to suspicion of a coexistent AD pathology.

7 June 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
VBValentina Bessi
Valentina Bessi
SMSalvatore Mazzeo
Salvatore Mazzeo
SBSilvia Bagnoli
Silvia Bagnoli
GGGiulia Giacomucci
Giulia Giacomucci
AIAssunta Ingannato
Assunta Ingannato
Benedetta NacmiasBenedetta Nacmias
Benedetta Nacmias
The Huntingtin gene (HTT) is within a class of genes containing a key region of CAG repeats. When expanded beyond 39 repeats, Huntington disease (HD) develops. Individuals with less than 35 repeats are not associated with HD. Increasing evidence has suggested that CAG repeats play a role in modulating brain development and brain function. However, very few studies have investigated the effect of CAG repeats in the non-pathological range on cognitive performances in non-demented individuals. In this study, we aimed to test how CAG repeats’ length influences neuropsychological scores in patients with subjective cognitive decline (SCD) and mild cognitive impairment (MCI). We included 75 patients (46 SCD and 29 MCI). All patients underwent an extensive neuropsychological battery and analysis of HTT alleles to quantify the number of CAG repeats. Results: CAG repeat number was positively correlated with scores of tests assessing for executive function, visual–spatial ability, and memory in SCD patients, while in MCI patients, it was inversely correlated with scores of visual–spatial ability and premorbid intelligence. When we performed a multiple regression analysis, we found that these relationships still remained, also when adjusting for possible confounding factors. Interestingly, logarithmic models better described the associations between CAG repeats and neuropsychological scores. CAG repeats in the HTT gene within the non-pathological range influenced neuropsychological performances depending on global cognitive status. The logarithmic model suggested that the positive effect of CAG repeats in SCD patients decreases as the number of repeats grows.